Physician profile
Jaspreet Chahal
NPI 1558703801
$103,592.58
in general payments reported to CMS, 2019-2025
85 companies · $4,751 in 2025
The $4,751 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $1,424 · 2021: $4,746 · 2022: $40K · 2023: $45K · 2024: $6,951 · 2025: $4,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Food and Beverage: $9,524 · Travel and Lodging: $5,806 · Consulting Fee: $1,675 · Education: $585 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,925.00 |
| Food and Beverage | $9,524.47 |
| Travel and Lodging | $5,806.10 |
| Consulting Fee | $1,675.00 |
| Education | $584.57 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $83,019.46 | 2022-2024 | |
| Pfizer INC. | $3,385.57 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,747.56 | 2020-2025 | Imfinzi, Lynparza, Enhertu |
| Novartis Pharmaceuticals Corporation | $1,919.42 | 2020-2025 | |
| Janssen Biotech, INC. | $1,025.00 | 2020-2025 | Darzalex, Imbruvica, Tecvayli |
| Merck Sharp & Dohme LLC | $1,010.04 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $824.14 | 2020-2025 | Tukysa, Adcetris |
| Celgene Corporation | $781.28 | 2019-2025 | Reblozyl, Pomalyst |
| Abbvie INC. | $720.21 | 2019-2025 | Venclexta |
| Incyte Corporation | $578.62 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Amgen INC. | $428.11 | 2019-2024 | Kyprolis, Blincyto, Lumakras |
| Bayer Healthcare Pharmaceuticals INC. | $414.17 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $350.57 | 2022-2025 | Monoferric |
| Rigel Pharmaceuticals, INC. | $343.32 | 2020-2022 | |
| Glaxosmithkline, LLC. | $317.22 | 2021-2025 | Ojjaara, Jemperli, Zejula |
Show all 85 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $311.15 | 2019-2025 | |
| Daiichi Sankyo INC. | $270.77 | 2021-2025 | Enhertu, Vanflyta, Injectafer |
| Dova Pharmaceuticals | $249.34 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $249.20 | 2023-2025 | Orgovyx |
| Gilead Sciences, INC. | $240.85 | 2019-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $233.43 | 2020-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Alexion Pharmaceuticals, INC. | $226.42 | 2022-2025 | Ultomiris |
| Pharmaessentia USA Corporation | $213.77 | 2023-2025 | Besremi |
| Kite Pharma, INC. | $213.53 | 2020-2025 | Yescarta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.26 | 2021-2024 | Gilotrif |
| Lilly USA, LLC | $172.55 | 2021-2025 | Verzenio, Jaypirca |
| Pharmacyclics LLC, An Abbvie Company | $172.46 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $152.70 | 2019-2023 | Opdivo |
| Coherus Oncology, INC. | $139.54 | 2021-2025 | Loqtorzi |
| Aveo Pharmaceuticals, INC. | $131.85 | 2023-2025 | Fotivda |
| Jazz Pharmaceuticals INC. | $128.91 | 2020-2023 | |
| Genentech USA, INC. | $125.94 | 2021-2023 | Phesgo, Perjeta, Tecentriq |
| Regeneron Healthcare Solutions, INC. | $125.85 | 2021-2023 | Libtayo |
| Exelixis INC. | $114.26 | 2021-2025 | Cabometyx |
| Karyopharm Therapeutics INC. | $108.00 | 2021-2024 | Xpovio |
| Puma Biotechnology, INC. | $105.83 | 2019-2021 | |
| Beone Medicines USA, INC. | $96.39 | 2025 | Tevimbra |
| Array Biopharma INC | $95.78 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Astellas Pharma US INC | $77.04 | 2020-2025 | Vyloy |
| Adaptive Biotechnologies Corporation | $73.37 | 2022-2024 | Clonoseq |
| Sun Pharmaceutical Industries INC. | $72.78 | 2020-2024 | |
| Mirati Therapeutics, INC. | $70.00 | 2023 | Krazati |
| Deciphera Pharmaceuticals INC. | $62.35 | 2024-2025 | Qinlock, Romvimza |
| Emd Serono, INC. | $60.84 | 2020-2025 | |
| Taiho Oncology, INC. | $58.30 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.58 | 2022 | |
| Amneal Pharmaceuticals LLC | $54.64 | 2024-2025 | Neulasta, Avastin, Neupogen |
| Genmab U.S., INC. | $54.56 | 2024-2025 | Tivdak, Epkinly |
| Cardinal Health 414 LLC | $50.60 | 2023 | |
| Integra Lifesciences Corporation | $49.66 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Sirtex Medical INC | $48.18 | 2020-2023 | Sir-Spheres Microspheres |
| Tempus Ai, INC | $47.49 | 2025 | Xt Cdx |
| Eusa Pharma (US) LLC | $46.84 | 2021-2022 | |
| Myovant Sciences INC. | $46.04 | 2021-2022 | |
| Stemline Therapeutics INC. | $45.89 | 2023 | Orserdu |
| Secura Bio, INC. | $43.40 | 2019-2020 | |
| Beigene USA, INC. | $39.98 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $37.33 | 2024-2025 | Enjaymo, Sylvant |
| Octapharma USA, INC. | $35.75 | 2024 | Octagam Immune Globulin (Human) |
| Lexicon Pharmaceuticals, INC. | $32.95 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $31.49 | 2020 | |
| Amag Pharmaceuticals, INC. | $30.94 | 2021 | |
| Tersera Therapeutics LLC | $28.04 | 2022 | |
| Pharming Healthcare, INC. | $25.87 | 2023 | Ruconest |
| Clovis Oncology, INC. | $24.04 | 2020 | |
| Myriad Genetic Laboratories, INC. | $23.78 | 2024 | Myrisk |
| Epizyme, INC. | $23.32 | 2021 | |
| Organon LLC | $21.85 | 2021-2022 | |
| Caris Mpi, INC. | $21.77 | 2025 | Mi Cancer Seek |
| Blueprint Medicines Corporation | $20.10 | 2020 | |
| Medtronic Minimed, INC. | $19.23 | 2020 | |
| Iovance Biotherapeutics, INC. | $18.79 | 2025 | Amtagvi |
| G1 Therapeutics, INC. | $18.00 | 2022 | |
| Macrogenics, INC. | $16.60 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.39 | 2023 | Truxima |
| Aurobindo Pharma USA, INC. | $15.35 | 2019 | |
| Alnylam Pharmaceuticals INC. | $15.19 | 2021 | |
| Abbott Laboratories | $15.09 | 2025 | Freestyle Libre 3 |
| Eisai INC. | $14.95 | 2023 | |
| Kyowa Kirin, INC. | $14.20 | 2020 | |
| Spectrum Pharmaceuticals INC. | $13.32 | 2023 | Rolvedon |
| Medtronic USA, INC. | $12.54 | 2020 | |
| Dendreon Pharmaceuticals LLC | $12.53 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.74 | 2021 | |
| Agios Pharmaceuticals, INC. | $11.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaspreet Chahal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.